Biontech SE
BNTX102.020USD
-18.520-15.36%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
24.48BMarket Cap
LossP/E TTM
More Details of Biontech SE Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
Company codeBNTX
Company nameBiontech SE
IPO dateOct 10, 2019
Founded at2019
CEOProf. Ugur Sahin, M.D.
Number of employees6772
Security typeDepository Receipt
Fiscal year-endOct 10
AddressAn der Goldgrube 12
CityMAINZ
Stock exchangeNASDAQ Global Select Consolidated
CountryGermany
Postal code55131
Phone4949613190840
Websitehttps://www.biontech.com/
Company codeBNTX
IPO dateOct 10, 2019
Founded at2019
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Revenue Breakdown
Currency: EURUpdate time: Wed, Mar 12
Currency: EURUpdate time: Wed, Mar 12
FY2019
FY2018
FY2017
By BusinessEUR
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
No Data
By Business
By Region
By BusinessEUR
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Shareholder
Update time: Thu, Mar 13
Update time: Thu, Mar 13
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Shareholder Statistics
Shareholder
Proportion
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Type
Shareholder
Proportion
Corporation
60.82%
Investment Advisor
15.74%
Investment Advisor/Hedge Fund
3.45%
Individual Investor
2.41%
Hedge Fund
0.93%
Sovereign Wealth Fund
0.75%
Research Firm
0.65%
Pension Fund
0.21%
Bank and Trust
0.18%
Other
14.86%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
822
205.15M
85.49%
+3.95M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
2022Q4
937
198.79M
81.74%
-3.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AT Impf GmbH
101.85M
42.44%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.43M
16.85%
-7.37K
-0.02%
Dec 31, 2024
Baillie Gifford & Co.
8.22M
3.43%
-87.49K
-1.05%
Dec 31, 2024
Fidelity Management & Research Company LLC
6.45M
2.69%
+1.27M
+24.48%
Dec 31, 2024
Flossbach von Storch AG
4.41M
1.84%
+47.24K
+1.08%
Dec 31, 2024
PRIMECAP Management Company
4.30M
1.79%
-220.70K
-4.89%
Dec 31, 2024
Pfizer Inc
3.66M
1.52%
+3.66M
--
Dec 31, 2024
Sahin (Ugur MD)
2.77M
1.16%
+1.92M
+224.09%
Dec 31, 2024
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Dec 31, 2024
Wolfgang (Jeggle Helmut)
1.43M
0.59%
-100.00K
-6.55%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Global X Genomics & Biotechnology ETF
4.75%
Langar Global HealthTech ETF
4.42%
iShares Genomics Immunology and Healthcare ETF
4.13%
First Trust NYSE Arca Biotechnology Index Fund
2.86%
Franklin Genomic Advancements ETF
2.33%
VanEck Biotech ETF
2.2%
Range Cancer Immunotherapy ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.51%
iShares Biotechnology ETF
1.38%
First Trust International Equity Opportunities ETF
1.33%
View more
Global X Genomics & Biotechnology ETF
Proportion4.75%
Langar Global HealthTech ETF
Proportion4.42%
iShares Genomics Immunology and Healthcare ETF
Proportion4.13%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.86%
Franklin Genomic Advancements ETF
Proportion2.33%
VanEck Biotech ETF
Proportion2.2%
Range Cancer Immunotherapy ETF
Proportion1.61%
Virtus LifeSci Biotech Products ETF
Proportion1.51%
iShares Biotechnology ETF
Proportion1.38%
First Trust International Equity Opportunities ETF
Proportion1.33%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data